



**WILLIAMS, MORGAN & AMERSON, P.C.**

7676 HILLMONT, SUITE 250, HOUSTON, TX 77040  
(713) 934-7000 FAX (713) 934-7011

Danny L. Williams  
Terry D. Morgan  
J. Mike Amerson  
Kenneth D. Goodman  
Barbara S. Kitchell, Ph.D.  
Jeffrey A. Pyle  
Ruben S. Bains  
Jaison C. John  
Randall C. Furlong, Ph.D.

FEB 1 / 2000  
TECH CENTER 1600/2900

GAU 1643 #6  
py  
2-18-00


Scott F. Diring\*  
Jeff E. Hundley, Ph.D.\*  
George J. Oehling\*  
Shelley P.M. Fussey, Ph.D.\*  
Mark D. Moore, Ph.D.\*  
David W. Hibler, Ph.D.\*  
Carolanne M. King\*  
Louis H. Iselin, Ph.D.\*  
Raymund F. Eich, Ph.D.\*

\*Patent Agent

WRITER'S DIRECT DIAL:  
(713) 934-4079

February 10, 2000

FILE: 4001.002282

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:	
February 10, 2000 Date	 Shelley P.M. Fussey

Assistant Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application Serial No. 09/351,862; Entitled: "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; Inventor(s): Thorpe and Ran; Client Reference: UTSMC/DAL:549--1*

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO-Form 1449 and references (C45-C48).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/002282.

WILLIAMS, MORGAN & AMERSON, P.C.

Assistant Commissioner for Patents

February 10, 2000

Page 2

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'SPF', is written above the printed name.

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Patent Agent

Encls.



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

February 10, 2000

Date

  
Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING  
ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1643

Examiner: Unknown

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98 (a)(3), a concise explanation of the relevance of the foreign language document submitted (Tobelem, 1990; Reference C47), as it is presently understood, is supplied. The statement submitted takes the form of the abstract of the reference, which is the only English text available. Applicants' submission of this information alone is motivated solely by the high cost of obtaining a translation of the full length document, and should in no way be interpreted as a failure to comply with the duty of disclosure or an intent to deceive the Examiner.

Tobelem, 1990:

"Summary: Anti-phospholipid antibodies: specificity and mechanism of action.

Circulating lupus-type anticoagulant is associated with an increased risk of arterial or venous thrombosis. The laboratory identification of lupus coagulant requires at least 2 different *in vitro* phospholipid-dependent coagulation techniques: immunological assessment based upon Elisa-type tests using pure phospholipids complements the coagulation procedure, but does not replace it. Circulating lupus anticoagulant is correlated with anti-phospholipid antibodies specific to phosphatidyl serine. Relationships between circulating lupus anticoagulant and anti-cardiolipin seem complex and are discussed. In fact, an entire family of anti-phospholipid antibodies exists, whose relationship with clinical manifestations remains to be determined. The effects of anti-phospholipid antibodies on human endothelial cells are described.


*Key words:* Systemic lupus erythematosus - Anti-phospholipid antibodies  
- Circulating lupus anticoagulant - Thromboses."

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than

three months prior to the filing of the present statement, as evidenced by the date of the enclosed search report (January 26, 2000).

In any event, the present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

  
\_\_\_\_\_  
Shelley P.M. Fussey  
Reg. No. 39,458  
Agent for Applicants

WILLIAMS, MORGAN & AMERSON  
7676 Hillmont, Suite 250  
Houston, Texas 77040  
(713) 934-7000

Date: February 10, 2000